[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cocaine-use\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cocaine-use":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,53],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100514108","rtms-and-cognitive-behavioral-therapy-for-cocaine-use-disorder-100514108",false,"NCT05974202","rTMS and Cognitive-behavioral Therapy for Cocaine Use Disorder","Augmenting Cognitive-behavioral Therapy With rTMS of the Medial Prefrontal and Anterior Cingulate Cortices for the Treatment of Cocaine Use Disorder","Inclusion Criteria:\n\n1. Age 22-65;\n2. Able to give informed consent and comply with study procedures;\n3. Meets DSM-5 criteria for current moderate\u002Fsevere CUD and are treatment-seeking;\n4. Used cocaine at least 9 days in the past 28 days, with at least weekly cocaine use;\n5. Agree to no more than moderate alcohol consumption (\\\u003C15 drinks\u002Fweek for men and \\\u003C8 drinks\u002Fweek for women) and to avoid using amphetamine\u002Fmethamphetamine and non-prescribed benzodiazepines or barbiturates; and\n6. Women of childbearing potential must agree to use a method of contraception with proven efficacy and agree to not become pregnant during the study.\n\nExclusion Criteria:\n\n1. Meets DSM-5 criteria for current moderate\u002Fsevere major depressive episode, OCD, bipolar disorder, schizophrenia or any psychotic disorder other than transient psychosis due to substance use;\n2. Hamilton Depression Rating Scale score \\> 17;\n3. Young Mania Rating Scale score \\>10;\n4. Meets DSM-5 criteria for current moderate\u002Fsevere other substance use disorder (aside from tobacco use disorder; physiologic dependence on any other substance other than nicotine, including alcohol, is exclusionary);\n5. Heavy weekly alcohol drinking as defined by an average of \\>14 drinks\u002Fweek for men or \\>7 drinks\u002Fweek for women on average during the past 28 days;\n6. Prior alcohol, benzodiazepine, or barbiturate withdrawal that resulted in hospitalization, medical detoxification, or resulted in seizures or delirium tremens;\n7. More than twice weekly use of non-prescribed medications\u002Fdrugs that may change the seizure threshold, including benzodiazepines, barbiturates, GHB\u002FGBL, amphetamines\u002Fmethamphetamine;\n8. Any other current DSM-5 psychiatric disorder(s) that in the investigator's judgment are unstable, would be disrupted by study procedures, or are likely to require pharmacotherapy or psychotherapy during the study period;\n9. Significant current suicide risk, indicated by either: (1) \"yes\" response on #3, 4, or #5 on the C-SSRS and a psychiatric risk assessment indicating a moderate or high risk of suicide or (2) suicidal behavior in the past 3 months (note: non-suicidal self-injurious behavior is not exclusionary);\n10. Females with a positive urine pregnancy test;\n11. Clinically significant abnormal cardiac functioning per electrocardiogram (ECG) (required for any participant age 60 years and older);\n12. Seizure history including: seizure disorder\u002Fepilepsy, alcohol\u002Fdrug withdrawal seizure, or seizure deemed by the study physician to be related to cocaine intoxication\u002Fwithdrawal (note: febrile seizures are not exclusionary)\n13. Other medical conditions that are relatively contraindicated with TMS (seizure disorders, glaucoma, increased intracranial pressure, severe migraines, stroke, brain lesions, pregnancy or breast-feeding, neurodegenerative disease, meningoencephalitis, intracerebral abscess, parenchymal or leptomeningeal cancers);\n14. Medications that lower seizure threshold and in the opinion of the investigator impose significant seizure risk for the individual (including bupropion, antipsychotics, lithium, anticholinergics, and tricyclic antidepressants);\n15. Cognitive disorder (MMSE \\\u003C25);\n16. Disqualifying response on the TMS Adult Safety Screen (TASS);\n17. Implanted devices or stimulators (cardiac pacemakers, vagus nerve stimulators, spinal cord stimulators, cochlear implant);\n18. Currently taking ototoxic medications (aminoglycosides, cisplatin);\n19. Metal implants or paramagnetic objects in the body that prohibits MR scanning;\n20. Claustrophobia that prohibits MR scanning; or\n21. Legally mandated (e.g., to avoid incarceration or other penalties) to participate in SUD treatment program.","ALL","22 Years","65 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to compare the effects of active repetitive transcranial magnetic stimulation (rTMS) to sham (placebo) rTMS prior to cognitive-behavioral therapy (CBT) as a treatment for adults with cocaine use disorder. The main questions it aims to answer are:\n\n* Is rTMS safe and feasible as an augmentation for CBT for the treatment of cocaine use disorder?\n* What is the brain mechanism of rTMS?\n* Will active rTMS (compared to sham rTMS) followed by CBT help adults with cocaine use disorder achieve abstinence from cocaine?\n\nParticipants will:\n\n* Have two brain MRI scans;\n* Undergo 3 weeks of daily rTMS (or sham) treatments (15 sessions), and;\n* Have 12 weeks of once-weekly cognitive-behavioral therapy for the treatment of cocaine use disorder.\n\nResearchers will compare active (real) rTMS to sham (placebo) rTMS. All participants will receive cognitive-behavioral therapy.\n\nThe former principle investigator, Dr. Derek Blevins, has vacated his position (February 2025), and has transferred the principle investigator role to Dr. John Mariani, the STARS Clinic Director.",[27,28,29,30,31],"Cocaine Use","Cocaine Dependence","Cocaine Use Disorder","Cocaine Use Disorder, Moderate","Cocaine Use Disorder, Severe",[33,34,35,36,37,38,39],"Repetitive transcranial magnetic stimulation","rTMS","TMS","Cognitive behavioral therapy","CBT","Functional magnetic resonance imaging","fMRI","NOT_YET_RECRUITING","2026-04-06",{"date":43,"type":44},"2026-04-07","ACTUAL",{"date":46,"type":21},"2026-05-01",{"date":48,"type":21},"2028-04-28",{"name":50,"class":51},"New York State Psychiatric Institute","OTHER",1,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":16,"minAge":59,"maxAge":4,"enrollmentInfo":60,"targetDuration":4,"studyType":22,"phases":62,"briefSummary":63,"conditions":64,"keywords":70,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":5},"100433670","encouraging-abstinence-behavior-in-a-drug-epidemic-optimizing-dynamic-incentives-100433670","NCT04927143","Encouraging Abstinence Behavior in a Drug Epidemic: Optimizing Dynamic Incentives","Inclusion Criteria:\n\n* Age at least 18 years old;\n* Meet DSM-5 OUD, CoUD, or MUD criteria as evidenced by an OUD CPT code F11\\* (opioid related disorders), a CoUD CPT code F14\\* (cocaine related disorders), a MUD CPT code F15.1\u002FF15.2 or other clinical notes indicating illicit opioid\u002Fcocaine\u002Fmethamphetamine use for treatment\n* Have access to a smartphone (iOS or Android) with data plan and willing to download DynamiCare app;\n* Have an email and can access it from their smartphone;\n* Are in residential, day (PHP), partial day (IOP), or outpatient (OP) AODA treatment;\n* Are likely to be helped by contingency management because at least ONE of the following conditions is true:\n\n  1. Were first enrolled in residential, PHP, or IOP substance use treatment no longer than 2 treatment weeks (14 days\u002Fencounters of treatment) prior to providing informed consent.\n  2. Used non-medical opioids, cocaine, and\u002For methamphetamine within the last 21 days.\n* Understands English.\n\nExclusion Criteria:\n\n* Have evidence of active (non-substance related) psychosis that might impair participation as determined by the PI.\n* Has significant cognitive impairment that might confound participation as determined by the PI or are so significantly cognitively impaired that they have a legal guardian.","18 Years",{"count":61,"type":21},600,[24],"Combatting the rise of the opioid epidemic is a central challenge of U.S. health care policy. A promising approach for improving welfare and decreasing medical costs of people with substance abuse disorders is offering incentive payments for healthy behaviors. This approach, broadly known as \"contingency management\" in the medical literature, has repeatedly shown to be effective in treating substance abuse. However, the use of incentives by treatment facilities remains extremely low. Furthermore, it is not well understood how to design optimal incentives to treat opioid abuse. This project will conduct a randomized evaluation of two types of dynamically adjusting incentive schedules for people with opioid use disorders or cocaine use disorders: \"escalating\" schedules where incentive amounts increase with success to increase incentive power, and \"de-escalating\" schedules where incentive amounts decrease with success to improve incentive targeting. Both schemes are implemented with a novel \"turnkey\" mobile application, making them uniquely low-cost, low-hassle, and scalable. Effects will be measured on abstinence outcomes, including longest duration of abstinence and the percentage of negative drug tests. In combination with survey data, variation from the experiment will shed light on the barriers to abstinence more broadly and inform the understanding of optimal incentive design.",[65,29,66,27,67,68,69],"Opioid-use Disorder","Opioid Use","Substance Use","Methamphetamine Abuse","Methamphetamine-dependence",[71,72],"contingency management","app-based treatment","RECRUITING","2026-02-09",{"date":76,"type":44},"2026-02-12",{"date":78,"type":44},"2021-09-15",{"date":80,"type":21},"2026-09",{"name":82,"class":51},"Wake Forest University Health Sciences"]